Literature DB >> 11573532

Evaluation and comparison of the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in the male rat.

D Zhu1, M D Wang, T Bäckström, G Wahlström.   

Abstract

We have evaluated and compared the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in male rats. A threshold method was used, and the first burst suppression period of 1 s or more in the EEG was selected as the end-point after fairly slow infusions. An optimal dose of 4.0 mg kg(-1) min(-1) was noted for both steroids. Brain concentrations were low at low infusion rates, indicating that acute tolerance was not occurring. Significant positive correlations were noted between dose rate and serum concentrations of allopregnanolone (r = 0.94, P<0.001) and pregnanolone (r = 0.88, P<0.001). Such correlations were also seen in striatum, cerebellum, cortex and muscle for both steroids (P<0.01). Despite changing infusion rates, the concentrations of both steroids in brainstem, hippocampus and fat remained stable. Because no correlation between infusion rate and steroid concentration was noted in the brainstem and hippocampus, these two brain areas may be regarded as primary sites of action for allopregnanolone and pregnanolone. Pregnanolone concentrations in the brainstem and hippocampus were significantly higher than those of allopregnanolone, suggesting that allopregnanolone was more potent than pregnanolone in inducing anaesthesia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573532     DOI: 10.1093/bja/86.3.403

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  16 in total

1.  Cellular GABAergic Neuroactive Steroid (3α,5α)-3-Hydroxy-Pregnan-20-One (3α,5α-THP) Immunostaining Levels Are Increased in the Ventral Tegmental Area of Human Alcohol Use Disorder Patients: A Postmortem Study.

Authors:  Ahmet Sait Hasirci; Antoniette M Maldonado-Devincci; Matthew C Beattie; Todd K O'Buckley; A Leslie Morrow
Journal:  Alcohol Clin Exp Res       Date:  2017-01-09       Impact factor: 3.455

2.  Pharmacokinetic and behavioral effects of allopregnanolone in healthy women.

Authors:  Erika Timby; Matts Balgård; Sigrid Nyberg; Olav Spigset; Agneta Andersson; Joanna Porankiewicz-Asplund; Robert H Purdy; Di Zhu; Torbjörn Bäckström; Inger Sundström Poromaa
Journal:  Psychopharmacology (Berl)       Date:  2005-09-21       Impact factor: 4.530

3.  The interaction between ethanol and pregnanolone at induction of anaesthesia investigated with a threshold method in male rats.

Authors:  M D Wang; D Zhu; T Bäckström; G Wahlström
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.

Authors:  Erika Timby; Torbjörn Bäckström; Sigrid Nyberg; Hans Stenlund; Anna-Carin N Wihlbäck; Marie Bixo
Journal:  Psychopharmacology (Berl)       Date:  2016-03-10       Impact factor: 4.530

Review 5.  Tolerance to allopregnanolone with focus on the GABA-A receptor.

Authors:  Sahruh Turkmen; Torbjorn Backstrom; Goran Wahlstrom; Lotta Andreen; Inga-Maj Johansson
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

6.  Tolerance to the rate-increasing and not rate-decreasing effects of pregnanolone in rats.

Authors:  Amy K Eppolito; Lisa R Gerak
Journal:  Behav Pharmacol       Date:  2010-12       Impact factor: 2.293

Review 7.  The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

8.  Beyond the HPA Axis: Progesterone-Derived Neuroactive Steroids in Human Stress and Emotion.

Authors:  Michelle M Wirth
Journal:  Front Endocrinol (Lausanne)       Date:  2011-08-11       Impact factor: 5.555

Review 9.  Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.

Authors:  Ronald W Irwin; Christine M Solinsky; Roberta Diaz Brinton
Journal:  Front Cell Neurosci       Date:  2014-07-30       Impact factor: 5.505

10.  Brexanolone as adjunctive therapy in super-refractory status epilepticus.

Authors:  Eric S Rosenthal; Jan Claassen; Mark S Wainwright; Aatif M Husain; Henrikas Vaitkevicius; Shane Raines; Ethan Hoffmann; Helen Colquhoun; James J Doherty; Stephen J Kanes
Journal:  Ann Neurol       Date:  2017-09-11       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.